Balakrishnan Biji, Soman Dawlee, Payanam Umashanker, Laurent Alexandre, Labarre Denis, Jayakrishnan Athipettah
Department of Biosciences & Bioengineering, Indian Institute of Technology Bombay, Mumbai, Maharashtra 400 076, India.
In Vivo Models and Testing Division, BMT Wing, Sree Chitra Tirunal Institute for Medical Sciences & Technology, Thiruvanthapuram, Kerala 695012, India.
Acta Biomater. 2017 Apr 15;53:343-354. doi: 10.1016/j.actbio.2017.01.065. Epub 2017 Jan 25.
A surgical adhesive that can be used in different surgical situations with or without sutures is a surgeons' dream and yet none has been able to fulfill many such demanding requirements. It was therefore a major challenge to develop an adhesive biomaterial that stops bleeding and bond tissues well, which at the same time is non-toxic, biocompatible and yet biodegradable, economically viable and appealing to the surgeon in terms of the simplicity of application in complex surgical situations. With this aim, we developed an in situ setting adhesive based on biopolymers such as chitosan and dextran. Dextran was oxidized using periodate to generate aldehyde functions on the biopolymer and then reacted with chitosan hydrochloride. Gelation occurred instantaneously upon mixing these components and the resulting gel showed good tissue adhesive properties with negligible cytotoxicity and minimal swelling in phosphate buffered saline (PBS). Rheology analysis confirmed the gelation process by demonstrating storage modulus having value higher than loss modulus. Adhesive strength was in the range 200-400gf/cm which is about 4-5 times more than that of fibrin glue at comparable setting times. The adhesive showed burst strength in the range of 400-410mm of Hg which should make the same suitable as a sealant for controlling bleeding in many surgical situations even at high blood pressure. Efficacy of the adhesive as a hemostat was demonstrated in a rabbit liver injury model. Histological features after two weeks were comparable to that of commercially available BioGlue®. The adhesive also demonstrated its efficacy as a drug delivery vehicle. The present adhesive could function without the many toxicity and biocompatibility issues associated with such products.
Though there are many tissue adhesives available in market, none are free of shortcomings. The newly developed surgical adhesive is a 2-component adhesive system based on time-tested, naturally occurring polysaccharides such as chitosan and dextran which are both biocompatible and biodegradable. Simple polymer modification has been carried out on both polysaccharides so that when aqueous solutions of both are mixed, the solutions gel in less than 10s and forms an adhesive that seals a variety of incisions. The strength of the adhesive is over 5-times the strength of commercially available Fibrin glue and is more tissue compliant than BioGlue®. This adhesive biomaterial showed excellent tissue bonding, was hemostatic, biocompatible and biodegradable. The significance of this work lies on the features of the developed tissue adhesive that it stops bleeding, bond the tissues well, can act as a drug delivery vehicle and would appeal to the surgeon in terms of the simplicity of application in complex surgical situations. There is no need for special delivery systems for application of this adhesive. The two-component adhesive can be applied one over the other using syringes. There is also no need for light curing with UV or visible light and the gelation between the two components spontaneously takes place on application leading to excellent tissue bonding.
一种可在有或没有缝线的不同手术情况下使用的手术粘合剂,是外科医生的梦想,但至今尚无一种能够满足诸多如此苛刻的要求。因此,开发一种能止血且能很好地粘结组织的粘合剂生物材料是一项重大挑战,这种材料同时还需无毒、具有生物相容性且可生物降解,经济可行,并且在复杂手术情况下应用简便,能吸引外科医生。出于这个目的,我们开发了一种基于壳聚糖和葡聚糖等生物聚合物的原位固化粘合剂。使用高碘酸盐氧化葡聚糖,在生物聚合物上生成醛基功能团,然后与壳聚糖盐酸盐反应。将这些组分混合后立即发生凝胶化,所得凝胶显示出良好的组织粘附特性,细胞毒性可忽略不计,在磷酸盐缓冲盐水(PBS)中肿胀最小。流变学分析通过证明储能模量的值高于损耗模量来证实凝胶化过程。粘附强度在200 - 400gf/cm范围内,在相当的固化时间下,约为纤维蛋白胶的4 - 5倍。该粘合剂的爆破强度在400 - 410mmHg范围内,这使得它即使在高血压情况下,在许多手术中也适合作为控制出血的密封剂。在兔肝损伤模型中证明了该粘合剂作为止血剂的功效。两周后的组织学特征与市售的BioGlue®相当。该粘合剂还证明了其作为药物递送载体的功效。这种新型粘合剂在使用时不存在与这类产品相关的许多毒性和生物相容性问题。
尽管市场上有许多组织粘合剂,但没有一种是没有缺点的。新开发的手术粘合剂是一种双组分粘合剂系统,基于经过时间考验的天然存在的多糖,如壳聚糖和葡聚糖,它们既具有生物相容性又可生物降解。对这两种多糖都进行了简单的聚合物改性,使得当它们的水溶液混合时,溶液在不到10秒内凝胶化,并形成一种能密封各种切口的粘合剂。该粘合剂的强度是市售纤维蛋白胶强度的5倍以上,并且比BioGlue®更贴合组织。这种粘合剂生物材料显示出优异的组织粘结性、止血性、生物相容性和可生物降解性。这项工作的意义在于所开发的组织粘合剂具有止血、能很好地粘结组织、可作为药物递送载体以及在复杂手术情况下应用简便从而能吸引外科医生等特点。应用这种粘合剂无需特殊的递送系统。这种双组分粘合剂可以使用注射器依次涂抹。也无需紫外线或可见光光固化,两种组分之间的凝胶化在涂抹时自发发生,从而实现优异的组织粘结。